Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Bristol-Myers Squibb CompanyNYSE: BMY
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation dips below year-ago levels
Q2 FY2026 stock-based compensation of $135M fell 1.5% year over year, behind the +4.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.
Context
- Stock-based compensation amounted to 1.1% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.5% toward the trailing-twelve-month pace of +4.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 553M USD
- Year-over-year change
- +9.1%
- 4-year CAGR
- -1.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 553M | +9.1% |
| FY2024 | 2024-12-31 | 507M | -2.1% |
| FY2023 | 2023-12-31 | 518M | +13.3% |
| FY2022 | 2022-12-31 | 457M | -21.6% |
| FY2021 | 2021-12-31 | 583M | — |
Stock-Based Compensation vs competitors
How BMY compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +4.3% is the 6th highest of 9, against a peer median of +5.1%.
- Stock-based compensation amounts to 1.1% of revenue for BMY, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.42B USD | +11.0% | +6.0% | 1.4% | |
| LTM Jun 2026 | $976M USD | +4.5% | +12.5% | 1.5% | |
| LTM Jun 2026 | $947M USD | +14.9% | -2.9% | 1.5% | |
| LTM Jun 2026 | $892M USD | +12.5% | — | 1.3% | |
| LTM Jun 2026 | $649.2M USD | +5.8% | +19.0% | 0.8% | |
| LTM Jun 2026 | $571M USD | -45.9% | — | 1.0% | |
| LTM Jun 2026 | $553M USD | +4.3% | +6.6% | 1.1% | |
| LTM Jun 2026 | $492M USD | -3.9% | +7.2% | 1.3% | |
| LTM Jun 2026 | $460M USD | -47.2% | +11.6% | 1.5% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | £0 GBP | — | — | 0.0% | |
| Peer median (excluding BMY) | — | +5.1% | +9.4% | 1.3% | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.01B | 6.35B | 8.04B | (8.93B) | 7.06B |
| Depreciation & Amortization | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B |
| Deferred Income Tax | (1.39B) | (2.74B) | (3.29B) | (2.09B) | (965M) |
| Stock-Based Compensation | 583M | 457M | 518M | 507M | 553M |
| Change in Working Capital | (1.26B) | (2.23B) | (1.91B) | 810M | (455M) |
| Accounts Receivables | (1.05B) | (663M) | (995M) | 264M | (295M) |
| Inventory | 13M | (69M) | (751M) | (486M) | (184M) |
| Accounts Payables | 245M | 109M | 198M | 184M | (2M) |
| Other Working Capital | (465M) | (1.61B) | (366M) | 848M | 26M |
| Other Non-Cash Items | 578M | 955M | 744M | 15.3B | 3.96B |
| Operating Cash Flow | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B |
| Capital Expenditures | (973M) | (1.12B) | (1.21B) | (1.25B) | (1.31B) |
| Acquisitions (Net) | (862M) | (2.98B) | (260M) | (20.72B) | (2.87B) |
| Purchases of Investments | (5.48B) | (3.59B) | (1.77B) | (769M) | (2B) |
| Sales of Investments | 6.78B | 6.63B | 948M | 1.39B | 2.05B |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (538M) | (1.06B) | (2.3B) | (21.35B) | (4.13B) |
| Debt Repayment | (6.18B) | (5.31B) | 456M | 10.1B | (5.18B) |
| Common Stock Issued | 0 | 0 | 0 | (106M) | (128M) |
| Common Stock Repurchased | (6.29B) | (8B) | (5.16B) | 0 | 0 |
| Dividends Paid | (4.4B) | (4.63B) | (4.74B) | (4.86B) | (5.05B) |
| Other Financing Activities | 641M | 984M | 27M | 0 | 0 |
| Financing Cash Flow | (16.22B) | (16.96B) | (9.42B) | 5.13B | (10.35B) |
| Effect of Forex Changes | (102M) | (33M) | 45M | (137M) | 187M |
| Net Change in Cash | (657M) | (4.99B) | 2.19B | (1.17B) | (137M) |
| Free Cash Flow | 15.23B | 11.95B | 12.65B | 13.94B | 12.85B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.